Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Last year (2022) CCAJ announced a.......
.....RS on December 9th and the PPS tanked. This year (2023) will CCAJ announce a reversal of the RS announcement on December 9th so the PPS can go back up?
It has been almost a year and no updates on this or any acquisitions or home-building!
I was thinking he would have to lower the price target since I recall the analysis included some progress with Adva-27a, which apparently won't happen anytime soon based on "pausing" the IND-enabling study at JGH.
Perhaps AEGIS will update their BUY rating and 1 year price target to reflect this new development regarding Adva-27a. I'm curious where they stand with the latest news.
Yes, just saw the 8K report as well. Looks like you were right in a post several weeks ago that the only thing that might save SBFM is Nora Pharma. At least they have revenue even though they don't make much profit! Time to set SBFM aside and move Nora to the forefront in 2024.
Why did Armistice Capital, LLC acquire more than 2,000,000 shares of SBFM in June 2023? Do they have some confidence in the future of SBFM? Just curious at this point.
When did you file with the SEC and what was the SEC response to you?
Anything related to below. Any significant positive update would be a miracle!
Adva-27a anticancer compound
In the area of oncology, our proprietary drug development activities have been focused on the development of a small molecule called Adva-27a for the treatment of aggressive forms of cancer. A Topoisomerase II inhibitor, Adva-27a has been shown to be effective at destroying Multidrug Resistant Cancer cells including Pancreatic Cancer cells, Breast Cancer cells, Small-Cell Lung Cancer cells and Uterine Sarcoma cells (Published in ANTICANCER RESEARCH, Volume 32, Pages 4423-4432, October 2012). We are the direct owner of all issued patents pertaining to Adva-27a including U.S. Patents Number 8,236,935 and 10,272,065.
Adva-27a is a GEM-difluorinated C-glycoside derivative of Podophyllotoxin. Another derivative of Podophyllotoxin called Etoposide is currently on the market and is used to treat various types of cancer including leukemia, lymphoma, testicular cancer, lung cancer, brain cancer, prostate cancer, bladder cancer, colon cancer, ovarian cancer, liver cancer and several other forms of cancer. Etoposide is one of the most widely used anticancer drugs. Adva-27a and Etoposide are similar in that they both attack the same target in cancer cells, namely the DNA unwinding enzyme, Topoisomerase II. Unlike Etoposide however, Adva-27a is able to penetrate and destroy Multidrug Resistant Cancer cells.
Adva-27a has been shown to have distinct and more desirable biological and pharmacological properties compared to Etoposide. In side-by-side studies using Multidrug Resistant Breast Cancer cells and Etoposide as a reference, Adva-27a showed markedly greater cell killing activity.
In February 2023, we signed a research agreement with the Jewish General Hospital (“JGH”), to complete the IND-enabling studies. The JGH has also agreed to negotiate with us the terms for Phase I Clinical Trials. Adva-27a’s initial indication will be pancreatic cancer for which there are currently little or no treatment options available. All aspects of the clinical trials in Canada will employ FDA standards at all levels.
K1.1 anticancer mRNA
In June 2021, we initiated a new research project in which we set out to determine if certain mRNA molecules can be used as anticancer agents. The data collected to date have shown that a selected group of mRNA molecules are capable of destroying cancer cells in vitro including multidrug resistant breast cancer cells (MCF-7/MDR), ovarian adenocarcinoma cells (OVCAR-3), and pancreatic cancer cells (SUIT-2). Studies using non-transformed (normal) human cells (HMEC cells) showed that these mRNA molecules had little cytotoxic effects. These new mRNA molecules, bearing the laboratory name K1.1, are readily adaptable for delivery into patients using the mRNA vaccine technology.
In April 2022, we filed a provisional patent application in the United States covering the subject mRNA molecules.
We recently concluded an agreement with a specialized partner for the purposes of formulating our K1.1 mRNA molecules into lipid nanoparticles, ready for use to conduct studies in xenograft mice. We anticipate commencing such studies within approximately the next twelve months.
SBFM-PL4 COVID-19 treatment
The initial genome expression products of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19, are two large polyproteins, referred to as pp1a and pp1ab. These two polyproteins are cleaved at 15 specific sites by two virus encoded proteases (Mpro and PLpro) to generate 16 different non-structural proteins essential for viral replication. Mpro and PLpro represent attractive anti-viral drug development targets as they play a central role in the early stages of viral replication. PLpro is of particular interest as a therapeutic target in that, in addition to processing viral proteins, it is also responsible for suppression of the human immune system making the virus more life-threatening. Our COVID-19 research effort has been focused on developing an inhibitor of PLpro, the viral enzyme that mediates suppression of the human immune system.
On May 22, 2020, we filed a patent application in the United States for a new treatment for Coronavirus infections. Our patent application covers composition subject matter pertaining to small molecules for inhibition of the Coronavirus main protease (Mpro) and papain-like protease (PLpro).
In February 2022, we expanded our PLpro inhibitors research effort by entering into a research agreement with the University of Arizona for the purposes of conducting research focused on determining the in vivo safety, pharmacokinetics, and dose selection properties of three University of Arizona owned PLpro inhibitors, to be followed by efficacy testing in mice infected with SARS-CoV-2 (the “Research Project”). Under the agreement, the University of Arizona granted the Company a first option to negotiate a commercial, royalty-bearing license for all intellectual property developed by University of Arizona personnel under the Research Project.
In addition, the Company and the University of Arizona entered into an Option Agreement whereby the Company was granted a first option to negotiate a royalty-bearing commercial license for the underlying technology of the Research Project. Encouraged by the results obtained to date, we submitted a Notice of Option Exercise to the University of Arizona on September 13, 2022.
I don't know how likely...maybe 50/50. In the filing I read it also said "if needed." We'll see where the price gets by February 2024!
They have to raise the price to $1+ somehow. There is more than one way so perhaps it will be based on a surprise positive progress report!
Is management making you happy now?
CCAJ is Pink Current again. Time to ramp up some positive news going into 2024!
https://www.otcmarkets.com/stock/CCAJ/profile
The filing said "if needed." Maybe they will have some exciting news about Nora Pharma and/or Covid and/or Cancer research prior to that for this to naturally rise to $1.00+ in early 2024!
Looks like SBFM is planning to stay listed either by merit-based price appreciation or a RS, whichever comes first within the next 6 months.
Did you make AXXA go down today? If you are in control of the price, can you make it go back up?
Great! I'm thinking of buying more based on this possibility. If it is rescinded then it might go back to $.005 where it was when they announced it last DEC!
Here's the related Covid article from UoA about Thatcher and SBFM licensing....
https://techlaunch.arizona.edu/news/uarizona-covid-19-treatment-takes-next-step-toward-public-impact-license-pharmaceutical
Found this News Interview of Gregory Thatcher (UofA) about the Covid treatment research that SBFM is involved with. Says they'll know by the end of 2023 if successful, then clinical trials in 2024!
https://www.kold.com/video/2023/03/01/university-arizona-inches-closer-new-covid-19-treatment/
Well....it depends. They got the 180-day extension to get the price back to $1.00+. Hopefully they can do it without a RS, but that is their backup plan per the news this morning.
Rather than an RS, can they leverage NoraPharma growth to grow the PPS? Do they have a positive update on their drug development to announce over next 3-4 months?
2024 appears to be the pivotal year!
SBFM sure has been disappointing this year and looks like no sign of a turnaround. Seems like they had some opportunities to turn things around, but have failed to do so.
Looks like the AEGIS BUY rating will be another failure even though it just came out in August.
Well...perhaps the SBFM rating is in the 14% group this time! That's all we got for now and 2024 is the year for Nora Pharma to show us the money!
Yes, I'm taking the AEGIS analyst report (including $3 target in 2024) as the best we have for now. They did have a note in their disclosure related to AEGIS (see below from the report). I've also included the direct link to the full report.
Price Target Summary: "The steady increase in revenues over the first six months of this year gives us greater confidence that Sunshine Biopharma could meet or beat our estimates for growth in sales of its generics business. Coupled with our belief that margins could also improve, we now have better data supporting our conviction that Sunshine could reach our goals of profitability by the end of 2024 and $100 million in annual sales for 2025. Therefore, we are raising our Target Price to $3 and affirming our Buy recommendation."
Research Analyst Disclosures: "I, David Bouchey, hereby certify that the views expressed in this research report accurately reflect my personal views about the subject companies and their securities. I also certify that I have not been, do not, and will not be receiving direct or indirect compensation in exchange for expressing the specific recommendations in this report. Research analyst compensation is not dependent upon investment banking revenues received by Aegis Capital Corp. Aegis Capital Corp. intends to seek or expects to receive compensation for investment banking services from the subject company within the next three months. The firm nor the Research Analyst have any material conflict of interest in which the Research Analyst has a reason to know or knows at the time of publication of this research report. As of the report date neither Aegis Capital Corp. or its affiliates beneficially own 1% or more of any class of common equity securities of the subject company of this report. Neither the research analyst who prepared this report or a member of the research analyst’s household has a financial position in the debt or equity securities of the subject company. Aegis Capital Corp. makes a market in Sunshine Biopharma Inc.. Aegis Capital Corp. has performed investment banking services for and received fees from Sunshine Biopharma Inc. within the past 12 months."
https://sunshinebiopharma.com/assets/analysts%20reports/20230814%20-%20Sunshine%20Biopharma%20Reports%20Q2-2023.pdf?_t=1693248489
I believe in the mice trials....they just haven't been able to bring these drugs to human trials! Speculation that this may still occur in late 2024-2025. In the meantime AEGIS says Nora Pharma should bring the price up (Target = $3) because they are growing revenue each quarter.
So, the only hope is if Nora Pharma can take the lead of this company? Seems like that is what AEGIS is saying needs to happen to get the price back up to $3 sometime in 2024. AEGIS needs to put pressure on SBFM management to put Nora Pharma in charge for the good of everyone.
I guess AEGIS is way off on their BUY rating thinking SBFM could get back to $3/share by 2024 based on Nora Pharma revenue growth alone, (given the drug development in the pipeline is still a ways off for clinical trials in late 2024)! Needless to say 2024 gives some time for the price to go back up, but not looking good as of today.
SBFM BUY Rating Target Price Increased to $3/share........
Sunshine Biopharma Inc.
Rating: Buy
Sunshine Biopharma Beats Our Revenue
Expectations - Raising Our Target Price to $3.
Full Report: https://sunshinebiopharma.com/assets/analysts%20reports/20230814%20-%20Sunshine%20Biopharma%20Reports%20Q2-2023.pdf?_t=1693248489
I think AXXA could be between $.50-1.00 in 2024 and I'm sticking with this prediction for now!
From today's low price it appears that nobody expects that to happen or that SBFM has any positive updates on their Cancer and Covid research projects! You would think they would have made some progress in the past 6-12 months.
Yes, we need some NORA sunshine soon!
Are you GIDDY about AXXA going UP soon? GIDDYUP!
What will happen to Nora Pharma when the Titanic sinks?
So are you saying this is for a Merger/Acquisition and not a R/S vote?
Is this more bad news for SBFM (see link)? Seems to be a precurser to a R/S vote? All opinions welcomed!
https://ih.advfn.com/stock-market/NASDAQ/sunshine-biopharma-SBFM/stock-news/91901043/form-pre-14a-other-preliminary-proxy-statements
And per the Q reports, the Float has stayed the same which was the only good news thus far!
Float: 593,902,574 as of June 30, 2023.
Even if the recent Q reports aren't complete at least they give this board something to talk and speculate about instead of silence!
Yes, still a lot of unanswered questions. The only thing new are the filed reports even though they are missing the financial info. I assume we will see Amended reports soon. My assumption is they finally filed both Q reports to get current again, but need to amend/complete the reports. We'll see how this all pans out in the coming days/weeks/months. I'm not expecting to know the reality until 2024, whether good or bad!
I see some new filings on OTC Markets. Looks like CCAJ is getting closer to Current again.
Let's just keep AXXA going up 10%+ per day and we'll all be fine!
Thanks. We need some answers even if not directly from the company!
Thanks for the queries and let us know if you do get anymore info. I also noted Jaybee is back saying he can help fix CCAJ. We shall see!
Each graph is different and the CCAJ graph is exactly what we saw happen since 2019!
All I'm saying is somehow CCAJ got in the TOP 6 for this publication.